AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...

In a challenging market environment, Hemispherx Biopharma Inc (NYSE:AIM), trading under the ticker AIM, has seen its stock price touch a 52-week low, reaching a sobering $0.13, marking an 82% decline ...

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on February 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for ...

AIM ImmunoTech Inc. announced plans to advance its drug Ampligen as a vaccine adjuvant for avian influenza, marking a new initiative in its antiviral development pipeline. The company has ...

Louisiana Surgeon General Ralph Abraham sent a directive to state health workers Thursday ending long-standing mass ...

HONG KONG SAR – media OutReach Newswire – 5 February 2025 – AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV ...

(MENAFN- Dubai PR Network) data-text="AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." data-link=" Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S." class ...

HONG KONG SAR - Media OutReach Newswire - 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...